Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1869-1877. doi: 10.1007/s00259-019-04388-3. Epub 2019 Jun 12.
Inflammatory FDG uptake in the lung (PET-pneumonitis) following curative-intent radiotherapy (RT)/chemo-RT (CRT) in non-small cell lung cancer (NSCLC) can pose a challenge in FDG-PET/CT response assessment. The aim of this study is to describe different patterns of PET-pneumonitis to guide the interpretation of FDG-PET/CT and investigate its association with tumor response and overall survival (OS).
Retrospective analysis was performed on 87 NSCLC patients in three prospective trials who were treated with radical RT (n = 7) or CRT (n = 80), with baseline and post-treatment FDG-PET/CT. Visual criteria were performed for post-treatment FDG-PET/CT response assessment. The grading of PET-pneumonitis was based on relative lung uptake intensity compared to organs of reference and classified as per Deauville score from grade 1-5. Distribution patterns of PET-pneumonitis were defined as follows: A) patchy/sub-pleural; B) diffuse (involving more than a segment); and C) peripheral (diffusely surrounding a photopenic region).
Follow-up FDG-PET/CT scans were performed approximately 3 months (median, 89 days; interquartile range, 79-93) after RT. Overall, PET-pneumonitis was present in 62/87 (71%) of patients, with Deauville 2 or 3 in 12/62 (19%) and 4 or 5 in 50/62 (81%) of patients. The frequency of patterns A, B and C of PET-pneumonitis was 19/62 (31%), 20/62 (32%) and 23/62 (37%), respectively. No association was found between grade or pattern of PET-pneumonitis and overall response at follow-up PET/CT (p = 0.27 and p = 0.56, respectively). There was also no significant association between PET-pneumonitis and OS (hazard ratio [HR], 1.3; 95% confidence interval [CI], 0.6-2.5; p = 0.45). Early FDG-PET/CT response assessment, however, was prognostic for OS (HR, 1.7; 95% CI, 1.2-2.2; p < 0.001).
PET-pneumonitis is common in early post-CRT/RT, but pattern recognition may assist in response assessment by FDG-PET/CT. While FDG-PET/CT is a powerful tool for response assessment and prognostication, PET-pneumonitis does not appear to confound early response assessment or to independently predict OS.
在接受根治性放疗(RT)/放化疗(CRT)的非小细胞肺癌(NSCLC)患者中,肺部炎症性 FDG 摄取(PET-肺炎)可能对 FDG-PET/CT 反应评估构成挑战。本研究旨在描述不同的 PET-肺炎模式,以指导 FDG-PET/CT 的解读,并探讨其与肿瘤反应和总生存期(OS)的关系。
对 3 项前瞻性试验中 87 例接受根治性 RT(n=7)或 CRT(n=80)治疗的 NSCLC 患者进行回顾性分析,这些患者基线和治疗后均进行了 FDG-PET/CT 检查。对治疗后 FDG-PET/CT 反应评估进行了视觉标准检查。根据与参照器官的相对肺摄取强度对 PET-肺炎进行分级,并根据 Deauville 评分从 1-5 级进行分类。PET-肺炎的分布模式定义如下:A)斑片状/胸膜下;B)弥漫性(累及多个节段);C)外周性(弥漫性围绕一个透光区)。
RT 后约 3 个月(中位时间 89 天;四分位间距 79-93 天)进行了随访 FDG-PET/CT 扫描。总体而言,62/87(71%)例患者出现 PET-肺炎,12/62(19%)例患者的 Deauville 评分为 2 或 3 分,50/62(81%)例患者的评分为 4 或 5 分。PET-肺炎的 A、B 和 C 模式的频率分别为 19/62(31%)、20/62(32%)和 23/62(37%)。在随访 PET/CT 中,PET-肺炎的分级或模式与总体反应之间无显著相关性(p=0.27 和 p=0.56)。PET-肺炎与 OS 之间也无显著相关性(危险比 [HR],1.3;95%置信区间 [CI],0.6-2.5;p=0.45)。然而,早期 FDG-PET/CT 反应评估对 OS 具有预后意义(HR,1.7;95%CI,1.2-2.2;p<0.001)。
CRT/RT 后早期 PET-肺炎很常见,但模式识别可能有助于 FDG-PET/CT 的反应评估。尽管 FDG-PET/CT 是评估反应和预后的有力工具,但 PET-肺炎似乎不会影响早期反应评估,也不会独立预测 OS。